Market Intelligence

Access the latest earnings reports, market analysis, hot topics, and individual stock insights

Report Categories

View All

Recent Articles

View All
CD Rates Reach 4 APY as of May 27 2026 What Savers Need to Know Trump Pressures Major Banks Over Alleged Discrimination Against Conservatives Child Therapists Insights on Essential People Skills May Inform Corporate Training Approaches Latin American Leaders at WUF13 Push for Housing Finance Reform and ClimateResilient Urban Development US Consumer Inflation Accelerates to 38 in April Surpassing Forecasts CRS Q1 2026 Earnings EPS Beat Driven by Strong Demand in Aerospace and Defense Equinox Gold EQX Q1 2026 Earnings Marginal EPS Miss Amid Gold Price Tailwinds Shares Dip 2 LDI Q1 2026 Earnings EPS Misses Estimates by Wide Margin Shares Rise Despite Loss Barclays PLC BCS Q1 2026 Earnings EPS Surpasses Consensus by 1036 Stock Edges Lower UAA Q1 2026 Earnings EPS Falls Short of Expectations Amid Ongoing Turnaround Efforts CoDiagnostics Inc CODX Surges Over 36 Approaching Critical Resistance Yueda Digital Holding YDKG Holds Steady Near 080 as Consolidation Continues GreenTree Hospitality GHG Surges 536 as Stock Tests Key Resistance Level Ceragon Networks CRNT Holds Near Support as Tight Range Persists Young Professionals in Singapore Earn Well but Struggle with Financial Insecurity as Lifestyle Expectations Rise Baird Raises Price Target on RideNow Group RDNW on Strong SameStore Sales Performance SK Hynix Surpasses 1 Trillion Market Cap on AIDriven Demand Morgan Stanley Adjusts Palo Alto Networks Price Target Amid Shifting Cybersecurity Demand Bitcoin Edges Higher Amid Elevated Bond Yields and Geopolitical Optimism on USIran Relations Workday Shares Surge 14 as AI Strength Drives Up Margin Guidance BWA Q1 2026 Earnings EPS Beat Drives Positive Investor Sentiment Meta Settles Social Media Addiction Lawsuit with US School District Potentially Reshaping Legal Landscape AMWD Q1 2026 Earnings Strong EPS Beat Drives 72 Stock Surge BLTE Q4 2025 Earnings WiderthanExpected Loss as PreRevenue Biotech Remains Focused on Clinical Development